Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Nishitani, Shinobu ^a   Horie, Mayumi ^a   Ishizaki, Sonoko ^a   Yano, Hirohisa ^b  

^a Mamezou Co Ltd   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; CYTOCHROME P450 3A4; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; RAPTOR PROTEIN; REGULATOR PROTEIN; RHEB PROTEIN; RICTOR PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PRIMER DNA; TARGET OF RAPAMYCIN KINASE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; CYTOLOGY; GENE SILENCING; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINO ACIDS, BRANCHED-CHAIN; ANTIGENS, NEOPLASM; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84896700981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082346     Document Type: Article

References (34)

1. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 13: 730-737. PubMed: 9212098.
2. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284. doi:10.1038/nrc1590. PubMed: 15803154.
3. Li F, Tiede B, Massagué J, Kang Y (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17: 3-14. doi:10.1038/sj.cr.7310118. PubMed: 17179981.
4. Liu LL, Fu D, Ma Y, Shen XZ (2011) The power and the promise of liver cancer stem cell markers. Stem Cells Dev 20: 2023-2030. doi:10.1089/scd.2011. 0012. PubMed: 21651381.
5. Gatti L, Cossa G, Beretta GL, Zaffaroni N, Perego P (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 1: 4237-4249
6. Behbod F, Rosen JM (2005) Will cancer stem cells provide new therapeutic targets? Carcinogenesis 26: 703-711. doi:10.1093/carcin/bgh293. PubMed: 15459022.
7. Yamashita T, Honda M, Nio K, Nakamoto Y, Yamashita T et al. (2010) Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 70: 4687-4697. doi:10.1158/1538-7445.AM10-4687. PubMed: 20484035.
8. Bi Y, Liu G, Yang R (2011) mTOR regulates T-cell differentiation and activation in immunity and autoimmunity. Crit Rev Eukaryot Gene Expr 21: 313-322. doi:10.1615/CritRevEukarGeneExpr.v21.i4.20. PubMed: 22181701.
9. Hobbs RM, Seandel M, Falciatori I, Rafii S, Pandolfi PP (2010) Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1. Cell 142: 468-479. doi:10.1016/j.cell.2010.06.041. PubMed: 20691905.
10. Nishitani S, Ijichi C, Takehana K, Fujitani S, Sonaka I (2004) Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem Biophys Res Commun 313: 387-389. doi:10.1016/j.bbrc.2003.11.023. PubMed: 14684173.
11. Hagiwara A, Nishiyama M, Ishizaki S (2012) Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol 227: 2097-2105.
12. Ijichi C, Matsumura T, Tsuji T, Eto Y (2003) Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun 303: 59-64. doi:10.1016/S0006- 291X(03)00295-X. PubMed: 12646166.
13. Kajiwara K, Okuno M, Kobayashi T, Honma N, Maki T et al. (1998) Oral supplementation with branched-chain amino acids improves survival rate of rats with varbon tetrachloride-induced liver cirrhosis. Dig Dis Sci 43: 1572-1579. doi:10.1023/A:1018831302578. PubMed: 9690397.
14. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175. doi:10.1016/S0092-8674(02)00808-5. PubMed: 12150925.
15. Yatsuhashi H, Ohnishi Y, Nakayama S, Iwase H, Nakamura T, et al. (2011) Anti-hypoalbuminemic effect of branched-chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake. Hepato Res 41: 1027-1035.
16. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai HT (2010) Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine- induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 101: 460-467. doi:10.1111/j.1349-7006.2009.01402.x. PubMed: 19906067.
17. Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y et al. (2009) Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 44: 483-491. doi:10.1007/s00535-009-0031-0. PubMed: 19319465.
18. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K et al. (2006) Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35: 203-214. PubMed: 16737844.
19. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M et al. (1993) Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 18: 320-327. doi:10.1016/0270-9139(93)92802-7. PubMed: 8393423.
20. Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M et al. (2009) Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 50: 1936-1945. doi:10.1002/hep.23248. PubMed: 19885880.
21. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O (2010) Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 9: 57-60. doi:10.1186/1476-4598-9-57. PubMed: 20226010.
22. Zhang X, Rielland M, Yalcin S, Ghaffari S (2011) Regulation and function of FoxO transcription factors in normal and cancer stem cells: what have we learned? Curr Drug Targets 12: 1267-1283. doi:10.2174/138945011796150325. PubMed: 21443463.
23. Foster KG, Fingar DC (2010) Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony. J Biol Chem 285: 14071-14077. doi:10.1074/jbc.R109.094003. PubMed: 20231296.
24. Zeng Z, Sarbassov, dos D, Samudio IJ, Yee KW, Munsell MF et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512. doi:10.1182/blood-2006-06-030833. PubMed: 17179228.
25. Akcakanat A, Singh G, Hung MC, Meric-Bernstam F (2007) Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362: 330-333. doi:10.1016/j.bbrc.2007.07.151. PubMed: 17707343.
26. Maddrey WC (1985) Branched chain amino acid therapy in liver disease. J Am Coll Nutr 4: 639-650. doi:10.1080/07315724.1985.10720106. PubMed: 3935706.
27. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K et al. (2005) Long-Term Survival Study Group: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3: 705-713. doi:10.1016/S1542-3565(05)00017-0. PubMed: 16206505.
28. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69: 5627-5629. doi: 10.1158/0008-5472.CAN- 09-0654. PubMed: 19584271.
29. Julien LA, Carriere A, Moreau J, Roux PP (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30: 908-1021. doi:10.1128/MCB.00601-09. PubMed: 19995915.
30. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159. doi:10.1016/j.ccr.2008.12.017. PubMed: 19185849.
31. Mimeault M, Johansson SL, Batra KS (2012) Pathobiolgical implications of the expression of EGFR, pAKT, NF-kapperB and MIC-1 in prostate cancer stem cells and theor pronenies. PLOS ONE 7: 31919-31935. doi:10.1371/journal.pone.0031919.
32. Han M, Liu M, Wang Y, Chen X, Xu J et al. (2012) Antagonism of mir-21 reverses eptherial mesenchymal trasition and cancer stem cell phenotype through Akt/ERK1/2 inactivation by targeting PTEN. PLOS ONE 6: 39520-39530.
33. Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972-1983. doi:10.1053/j.gastro.2008.08.008. PubMed: 18929564.
34. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N et al. (2011) Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 253: 94-100. doi:10.1097/SLA.0b013e3181f9bc00. PubMed: 21233610.